Presently, 19 different GLP-1 analogues are in development for the treatment of obesity by almost as many companies
You take the tablet every morning on an empty stomach, making it easy to fit into your daily routine
FDA approval of exenatide, its first generic injectable GLP-1 agonist, Amneal (2024) Teva announces FDA approval and launch of generic Saxenda (liraglutide injection) first generic GLP-1 indicated for weight loss, Teva Pharmaceuticals (2025) Exenatide, DailyMed (2025) Byetta, DailyMed (2025) Liraglutide (generic Victoza), DailyMed (2025) Liraglutide (generic Saxenda), DailyMed (2025) Victoza, DailyMed (2025) Saxenda, DailyMed (2025) Compounding and the FDA: Questions and answers, U.S
Participants on a 5 mg dose lost 15.0% of their body weight compared to baseline
Originally developed for type 2 diabetes under the brand name Ozempic, semaglutide was later approved at a higher dose as Wegovy specifically for chronic weight management
Gupta N, Prasad PD, Ghamande S, Moore-Martin P, Herdman AV, Martindale RG, et al